665061Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211051708. doi: 10.1177/10760296211051708.
Carotid and vertebral artery dissections are estimated to account for ∼20% of strokes in patients under 45-years-old. This meta-analysis compared the efficacy and safety of treatment with anticoagulants versus antiplatelet agents to determine the optimal therapy. We searched 4 electronic databases for clinical trials published from January 1, 1980 to August 25, 2021 that included patients who received anticoagulant or antiplatelet therapy for carotid and/or vertebral artery dissections. The curative effect was judged by recanalization evaluated by imaging. The primary outcomes were all cause death and ischemic stroke; secondary outcomes included hemorrhage and transient ischemic attack (TIA). Patients who received only a single drug treatment were divided into antiplatelet or anticoagulant groups; all received conservative treatment without surgical intervention. For this investigation, we pooled the available studies to conduct a meta-analysis, which included 7 articles with 1126 patients. The curative effect of vascular recanalization was not significantly different between the 2 treatment groups (odds ratio [OR] = 0.913, 95% confidence interval [CI]: 0.611-1.365, = .657); similarly, no significant differences were found regarding the primary outcomes all cause death (OR = 1.747, 95%CI: 0.202-15.079, = .612) and ischemic stroke (OR = 2.289, 95%CI: 0.997-5.254, = .051). Patients treated with anticoagulants were more likely to experience TIA (OR = 0.517, 95%CI: 0.252-1.060, = .072) and hemorrhage (OR = 0.468, 95%CI: 0.210-1.042, = .063), but the differences were not statistically significant. Overall, there were no statistically significant differences between anticoagulant therapy and antiplatelet therapy for the treatment of carotid and vertebral artery dissections.
颈内动脉和椎动脉夹层约占 45 岁以下患者中风的 20%。本荟萃分析比较了抗凝治疗与抗血小板治疗的疗效和安全性,以确定最佳治疗方法。我们检索了 4 个电子数据库,纳入了 1980 年 1 月 1 日至 2021 年 8 月 25 日发表的临床试验,这些试验包含接受抗凝或抗血小板治疗的颈内动脉和/或椎动脉夹层患者。通过影像学评估血管再通来判断疗效。主要结局是全因死亡和缺血性卒;次要结局包括出血和短暂性脑缺血发作(TIA)。仅接受单一药物治疗的患者分为抗血小板或抗凝治疗组;所有患者均接受保守治疗而未进行手术干预。在本研究中,我们将可用的研究进行汇总以进行荟萃分析,共纳入 7 项研究,包含 1126 例患者。两组血管再通的疗效无显著差异(比值比[OR] = 0.913,95%置信区间[CI]:0.611-1.365, = 0.657);同样,两组主要结局全因死亡(OR = 1.747,95%CI:0.202-15.079, = 0.612)和缺血性卒(OR = 2.289,95%CI:0.997-5.254, = 0.051)也无显著差异。接受抗凝治疗的患者更有可能发生 TIA(OR = 0.517,95%CI:0.252-1.060, = 0.072)和出血(OR = 0.468,95%CI:0.210-1.042, = 0.063),但差异无统计学意义。总体而言,抗凝治疗与抗血小板治疗治疗颈内动脉和椎动脉夹层的疗效无统计学差异。